Abstract

Objective

Rheumatoid Arthritis (RA) is a progressive autoimmune disease characterized by chronic joint inflammation and structural damage. Remission or at least low disease activity (LDA) represent potentially desirable goals of RA treatment. Single nucleotide polymorphisms (SNPs) in several genes might be useful for prediction of response to therapy. We aimed at exploring 4 SNPs in candidate genes ($\text{STAT4}$, $\text{PTPN2}$, $\text{PSORS1C1}$ and $\text{TRAF3IP2}$) in order to investigate their potential role in the response to therapy with tumor necrosis factor inhibitors (TNF-i) in RA patients.

Methods

In 171 RA patients we investigated the following SNPs: rs7574865 ($\text{STAT4}$), rs2233945 ($\text{PSORS1C1}$), rs7234029 ($\text{PTPN2}$) and rs33980500 ($\text{TRAF3IP2}$). Remission, LDA, and EULAR response were registered at 6 months and 2 years after initiation of first line TNF-i [Adalimumab (ADA) and Etanercept (ETN)].

Results

$\text{STAT4}$ variant allele was associated with the absence of a good/moderate EULAR response at 2 years of treatment in the whole RA group and in ETN treated patients. The $\text{PTPN2}$ SNP was associated with no good/moderate EULAR response at 6 months in ADA treated patients. Patients carrying $\text{PSORS1C1}$ variant allele did not reach LDA at 6 months in both the whole RA group and ETN treated patients. $\text{TRAF3IP2}$ variant allele was associated with the lack of LDA and remission achievement at 6 months in all RA cohort while an association with no EULAR response at 2 years of treatment occurred only in ETN treated patients.
Conclusions
For the first time, we reported that SNPs in **STAT4**, **PTPN2**, **PSORS1C1**, and **TRAF3IP2** are associated with response to TNF-i treatment in RA patients; however, these findings should be validated in a larger population.

Introduction
Rheumatoid Arthritis (RA) is a progressive autoimmune disease characterized by chronic joint inflammation and structural damage [1]. The management of RA has undergone significant changes with the current “treat to target” strategy [2]. The introduction of biological disease modifying anti-rheumatic drugs (bDMARDs) has changed the face of RA with remission or at least low disease activity (LDA) as achievable goals [3, 4]. Predictive biomarkers of response to therapy with bDMARDs could enable selection of the optimal treatment for the individual patients. Evidence assessed the value of age, gender, concomitant drugs, body mass index, or smoking status for predicting response to treatment [5–7]. Moreover, RA disease duration, disease activity, functional status, presence of autoantibodies [rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA)], and previous therapies can influence drug response [8–11]. Genetic inter-individual variability can also contribute to the differences in the response to treatment: some single nucleotide polymorphisms (SNPs) showed an association with bDMARDs response and might be useful for prediction, although few associations have been replicated [12–15].

Some genes already known to be involved in RA susceptibility [16] could also be involved in the variability of the response to tumor necrosis factor (TNF)-inhibitors (TNF-i) drugs [15]. Among the known loci associated with RA, the signal transducer and activator of transcription 4 (**STAT4**) could be one of the most interesting candidate genes to study in relation to drug response [17]. A recent meta-analysis demonstrated that SNPs in **STAT4** confer susceptibility to RA in total subjects and in major ethnic groups. Moreover, this association was not dependent on RF and ACPA positivity [18]. The protein tyrosine phosphatase non-receptor 2 (**PTPN2**) is one of the newly investigated genes being recently reported as linked to the pathogenesis of RA [19–21]. Additional genetic associations with the development of RA have been suggested for **PSORS1C1/CDSN** and **TRAF3 Interacting Protein 2** (**TRAF3IP2**) genes that are well-known susceptibility genes for psoriasis and psoriatic arthritis [21–23].

Thus, the aim of our study was to investigate the potential role of SNPs in **STAT4**, **PTPN2**, **PSORS1C1**, and **TRAF3IP2** as predictors of remission and LDA in a cohort of RA patients treated with first line TNF-i.

Material and Methods
Patients
Medical records of RA patients referred to the Rheumatology Outpatient Clinic at the Department of “Medicina dei Sistemi” (“Policlinico Tor Vergata”, Rome, Italy), were retrospectively analyzed (time frame of the enrollment January 2008-December 2013). Patients were included in the study if they fulfilled the following inclusion criteria: the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA [24], ≥ 18 years of age, inadequate response to at least one conventional synthetic (cs) DMARD, including Methotrexate, naïve for biologic treatment. Patients were excluded from the study if they showed impairment of hepatic/renal function, alcohol abuse, recent infection...
(with the last infection >3 month ago), ongoing history of malignancy (with interval malignancy-free >5 years) or ongoing pregnancy, and if they had missing or incomplete data in the follow-up visits. Therefore, the study included 171 RA patients of Caucasian origin. Patients received recommended doses of TNF-i: subcutaneous injection of Adalimumab (ADA) at 40 mg bi-weekly or Etanercept (ETN) at 50 mg every week. Disease activity and clinical response to therapy were assessed using Simplified Disease Activity Index (SDAI; LDA: ≤ 11, remission: ≤ 3.3) [25], disease activity score on 28 joints [DAS28 based on C-reactive protein (CRP)], and EULAR response criteria [25, 26]. The clinical and laboratory findings were evaluated at baseline and every 3 months from the start of TNF-i therapy; data of LDA, remission and EULAR response were registered at 6 months and 2 years after the beginning of the TNF-i treatment. Laboratory assessment included CRP, RF and ACPA. CRP and RF levels were assessed by nephelometry (normal range, 0–3 mg/L and 0–10 IU, respectively). ACPA were detected with a commercial third generation automated chemiluminescent kit: values >20 IU were considered positive. Peripheral blood samples were obtained at the time of the first medical evaluation from all included RA patients in order to perform the genetic analyses. All patients were naïve for biologic treatments at the time of blood sampling. Samples were stored at -80˚C until they were analyzed. Written informed consent was obtained from patients. The study protocol was approved by the local ethics committee of the “Policlinico Tor Vergata” in Rome (Italy).

DNA extraction and genotyping

Genomic DNA was isolated from peripheral blood mononuclear cells using a Qiagen blood DNA mini kit. We have investigated the following SNPs, localized in the genes reported in parenthesis: rs7574865 (STAT4), rs7234029 (PTPN2), rs2233945 (PSORS1C1), and rs33980500 (TRAF3IP2). Genotyping was performed by allelic discrimination assay by TaqMan technology (Applied Biosystems, Foster City, CA, USA) and ABI PRISM 7000. Each assay was run including samples with known genotypes.

Statistical analysis

The Hardy–Weinberg equilibrium was verified for all SNPs by the Pearson $\chi^2$ test. We evaluated a possible correlation between the genetic variants and the SDAI LDA, SDAI remission and EULAR response, at 6 months and 2 years from the beginning of the TNF-i treatment. Differences in genotypes frequencies between groups of patients were evaluated by Pearson $\chi^2$ test or by the Fisher’s Exact test, where appropriate. Odds ratios (ORs) with 95% CI were calculated. A multivariate logistic regression analysis was used to correct the p-value for sex, csDMARDS and ACPA/RF positivity. All statistical analyses were performed by the SPSS program ver. 19 (IBM Corp, Armonk, NY USA). Two-tailed P values less than 0.05 were considered statistically significant.

Results

A total of 171 RA patients were included in the study, of whom 62.6% (n = 107) were treated with ETN and 37.4% (n = 64) were treated with ADA. Clinical and demographic data of the population are described in Table 1. Patients had longstanding disease in 72.5% of the cases. RF and ACPA were positive in 69.6% and 74.3% of patients, respectively. Mean SDAI at the beginning of the treatment was 27.6 ± 14. Patients with RA receiving concomitant csDMARDs comprised 77.2%. After 6 months of TNF-i treatment, SDAI remission was achieved in 26.7% of the whole RA population, SDAI-LDA was reached in 54% and a good-moderate EULAR response in 73.3% of patients. After 2 years of treatment, SDAI remission was achieved in
29.8%, SDAI-LDA in 63.5%, and a good-moderate EULAR response was reached in 77.9% of patients. At 2 years we observed 65 dropouts patients (38% of the whole study population) because of adverse events (n = 7, 10.7%), secondary failure (n = 33, 50.7%) and concomitant conditions (n = 25, 38.4%). No differences in demographic, clinical data and response to treatment were detected between subgroups of patients treated with ETN or ADA.

Associations of genetic variants with response to TNF-i treatment

We analyzed four SNPs in four candidate genes to investigate their possible role on TNF-i treatment response. In particular, we compared the genotypes distribution in relation to SDAI LDA (achieved vs not achieved), SDAI remission (achieved vs not achieved), and EULAR response (good/moderate vs no response). All the analyses were performed considering the clinical evaluations during follow up at 6 months and at 2 years after the treatment starting. Firstly, we performed a primary analysis considering the whole cohort of RA patients, independently from the specific administered TNF-i drug (Table 2). In accordance with this preliminary analysis the TRAF3IP2 SNP was associated with no achievement of LDA and remission at 6 months (P = 0.035 and OR = 0.36, P = 0.013 and OR = 0.11, respectively). These associations were confirmed after multiple correction for sex, csDMARDs and ACPA/RF positivity (P_adj = 0.03 and P_adj = 0.02 respectively). STAT4 SNP was associated with no EULAR response at 2 years of treatment (P = 0.05, OR = 0.38). Patients carrying PSORS1C1 variant allele did not reach LDA at 6 months (P = 0.002, OR = 0.35). The association with lack of achievement of LDA at 6 months was confirmed by the multiple correction (P_adj = 0.003, OR_adj = 0.36).

In a second step, we repeated the analysis with each drug considered separately and we observed that the associations were drug-specific, except for the TRAF3IP2 SNP (Table 3 and Table 4). Indeed, TRAF3IP2 SNP showed a trend for association with lack of achievement of remission in ETN and ADA treated patients at 6 months of treatment after adjusting for sex, csDMARDs and ACPA/RF positivity (ETN: P_adj = 0.08, OR_adj = 0.14; ADA: P_adj = 0.09, OR_adj = 0.14).

With regard to ETN treatment, we confirmed an association between EULAR response and STAT4 SNP: patients carrying the variant allele showed a worse EULAR response at 2 years with P = 0.013 and OR = 0.16 (confirmed also after correction for sex, DMARDs and ACPA/RF positivity, P_adj = 0.02 and OR_adj = 0.14). The lack of achievement of LDA was also observed.

Table 1. Demographic and clinical data of 171 patients with Rheumatoid Arthritis included in the study.

|                      | Etanercept N = 107 | Adalimumab N = 64 | All N = 171 |
|----------------------|--------------------|-------------------|-------------|
| Age (years)          | 54.4 ± 12.8        | 52 ± 13.5         | 53.6 ± 13.1 |
| Women, n (%)         | 80 (74.7)          | 52 (81.2)         | 132 (77.2)  |
| Disease duration (years) | 11.3 ± 18.2       | 10.7 ± 19.9       | 9.2 ± 18.8  |
| Early arthritis (< 2 years), n (%) | 31 (28.9)         | 16 (25)           | 47 (27.5)   |
| RF positivity, n (%) | 75 (70)            | 44 (68.7)         | 119 (69.6)  |
| ACPA positivity, n (%) | 79 (73.8)          | 48 (75)           | 127 (74.3)  |
| Baseline DAS28       | 5.2 ± 1.3          | 5.1 ± 1.2         | 5.2 ± 1.3   |
| Baseline SDAI        | 27.6 ± 14          | 26.5 ± 12.9       | 27.2 ± 13.6 |
| Concurrent csDMARDs, n (%) | 78 (72.9)         | 50 (78.1)         | 132 (77.2)  |
| Concurrent PDN, n (%) | 54 (50.4)          | 33 (51.5)         | 87 (50.9)   |

Data presented as number of patients (%) or mean ± SD. RF, Rheumatoid Factor; ACPA, anti-citrullinated peptide antibodies; DAS28, Disease Activity Score on 28 joints; SDAI, Simplified Disease Activity Index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; PDN, prednisone.

doi:10.1371/journal.pone.0169956.t001
Table 2. Association analysis between TRAF3IP2, STAT4, PSORS1C1 and PTPN2 polymorphisms and response to TNF-inhibitors treatment in RA patients.

| SNP and gene | Target | Response | Six months | Two years |
|--------------|--------|----------|------------|-----------|
|              |        | Genotypes | OR (95% CI) P adj* | Genotypes | OR (95% CI) P adj* |
|              |        | wt/hz/var |              | wt/hz/var |              |
| rs33980500 C>T TRAF3IP2 | SDAI_LDA Yes | 61/7/0 | 0.035 | 0.36 (0.14–0.96) | 0.03 | 0.33 (0.12–0.9) | 61/6/0 | 0.31 | 0.54 (0.16–1.81) | 0.31 | 0.53 (0.16–1.79) |
|              | No | 59/13/1 | | | | | 33/5/1 | | | |
|              | SDAI_remission Yes | 43/1/0 | 0.013 | 0.1 (0.02–0.87) | 0.02 | 0.09 (0.01–0.70) | 31/1/0 | 0.077 | 0.18 (0.02–1.47) | 0.11 | 0.18 (0.02–1.49) |
|              | No | 97/19/1 | | | | | 62/10/1 | | | |
|              | EULAR Good/moderate | 103/14/1 | 0.60 | 0.77 (0.29–2.04) | 0.45 | 0.68 (0.25–1.87) | 74/7/1 | 0.31 | 0.51 (0.14–1.89) | 0.32 | 0.51 (0.14–1.91) |
|              | No | 37/7/0 | | | | | 19/4/0 | | | |
| rs7574865 G>T STAT4 | SDAI_LDA Yes | 49/34/5 | 0.58 | 0.84 (0.45–1.56) | 0.54 | 0.82 (0.44–1.54) | 34/27/6 | 0.65 | 0.83 (0.38–1.84) | 0.6 | 0.81 (0.36–1.79) |
|              | No | 38/32/4 | | | | | 18/18/3 | | | |
|              | SDAI_remission Yes | 25/15/4 | 0.63 | 0.84 (0.42–1.69) | 0.68 | 0.86 (0.42–1.75) | 12/18/2 | 0.13 | 1.91 (0.82–4.48) | 0.12 | 2.0 (0.84–4.76) |
|              | No | 62/51/5 | | | | | 39/27/7 | | | |
|              | EULAR Good/moderate | 67/45/7 | 0.22 | 0.65 (0.32–1.3) | 0.22 | 0.64 (0.31–1.3) | 44/31/7 | 0.05 | 0.38 (0.14–1.02) | 0.06 | 0.38 (0.14–1.03) |
|              | No | 20/22/2 | | | | | 7/14/2 | | | |
| rs2233945 C>A PSORS1C1 | SDAI_LDA Yes | 65/21/2 | 0.002 | 0.35 (0.18–0.68) | 0.003 | 0.36 (0.19–0.71) | 41/25/1 | 0.82 | 0.91 (0.41–2.04) | 0.85 | 0.92 (0.41–2.08) |
|              | No | 37/33/4 | | | | | 23/13/3 | | | |
|              | SDAI_remission Yes | 31/11/2 | 0.23 | 0.63 (0.30–1.34) | 0.29 | 0.66 (0.31–1.41) | 23/8/1 | 0.13 | 0.5 (0.2–1.23) | 0.12 | 0.49 (0.2–1.21) |
|              | No | 71/43/4 | | | | | 41/29/3 | | | |
|              | EULAR Good/moderate | 79/37/3 | 0.16 | 0.61 (0.30–1.23) | 0.24 | 0.65 (0.32–1.33) | 46/34/2 | 0.05 | 2.82 (0.95–8.32) | 0.06 | 2.9 (0.97–8.67) |
|              | No | 24/17/3 | | | | | 18/3/2 | | | |
| rs7234029 A>G PTPN2 | SDAI_LDA Yes | 64/22/2 | 0.31 | 0.71 (0.36–1.38) | 0.25 | 0.66 (0.33–1.33) | 46/20/1 | 0.23 | 1.77 (0.7–4.5) | 0.24 | 1.77 (0.69–4.58) |
|              | No | 47/23/2 | | | | | 31/7/1 | | | |
|              | SDAI_remission Yes | 32/10/2 | 0.57 | 0.80 (0.37–1.73) | 0.42 | 0.72 (0.33–1.59) | 23/8/1 | 0.94 | 1.04 (0.41–2.62) | 0.93 | 1.05 (0.40–2.71) |
|              | No | 79/35/2 | | | | | 53/19/1 | | | |
|              | EULAR Good/moderate | 86/29/3 | 0.11 | 0.55 (0.26–1.14) | 0.08 | 0.5 (0.23–1.08) | 59/22/1 | 0.85 | 1.11 (0.39–3.15) | 0.77 | 1.17 (0.40–3.44) |
|              | No | 25/16/1 | | | | | 17/5/1 | | | |

* indicates the homozygous genotype for the wild-type allele; "hz" indicates the heterozygous genotype; "var" indicates the homozygous genotype for the variant allele.

* P adjusted for sex, DMARDS and ACPA/RF positivity. Significant P values are reported in bold.

doi:10.1371/journal.pone.0169956.t002

for patients carrying the variant allele of PSORS1C1 SNP (P = 0.012, OR = 0.35; after correction P adj = 0.023, OR adj = 0.37). Regarding the ADA treatment, we observed an association between EULAR response and TRAF3IP2 SNP at 2 years of treatment (P = 0.027, OR = 0.14): patients carrying the variant allele had a worse response to treatment. The PSORS1C1 SNP was associated with SDAI remission (P = 0.024) at 2 years of treatment, but the association was not confirmed after correction. Lastly, the PTPN2 SNP resulted associated with a worse EULAR response at 6 months of ADA treatment (P = 0.038, OR = 0.26), data partially confirmed also after multiple correction (P adj = 0.06, OR adj = 0.27).
| SNP and gene       | Target       | ETN Response | Six Months | Genotypes wt/hz/var | P (1d) | OR (95% CI) | OR adj (95% CI) | Two years | Genotypes wt/hz/var | P (1d) | OR (95% CI) | OR adj (95% CI) |
|-------------------|--------------|--------------|------------|---------------------|--------|-------------|-----------------|-----------|---------------------|--------|-------------|-----------------|
| rs33980500 C>T    | TRAF3/P2     | SDAI_LDA     | Yes        | 45/4/0              | 0.15   | 0.41 (0.12–1.42) | 0.13 (0.1–1.36) | 41/3/0    | 0.56               | 0.61 (0.11–3.26) | 0.61 (0.12–3.51) |
|                   |              | No           |            | 41/8/1              |        |             |                 | 25/2/1    |                    |        |             |                 |
|                   |              | SDAI_remission | Yes       | 28/1/0              | 0.096  | 0.17 (0.02–1.40) | 0.08 (0.02–1.23) | 21/1/0   | 0.43               | 0.42 (0.05–3.82) | 0.56 (0.05–4.98) |
|                   |              |              | No         | 58/11/1             |        |             |                 | 44/4/1    |                    |        |             |                 |
|                   |              | EULAR        | Good/moderate | 60/8/1             | 0.68   | 0.78 (0.24–2.55) | 0.75 (0.23–2.89) | 52/5/1   | 0.23               | ND     | 1            | ND              |
|                   |              |              | No         | 26/5/0              |        |             |                 | 13/0/0    |                    |        |             |                 |
| rs7574865 G>T     | STAT4        | SDAI_LDA     | Yes        | 23/2/3             | 0.84   | 1.09 (0.5–2.38) | 0.82 (0.48–2.50) | 21/19/4  | 0.91               | 0.95 (0.37–2.45) | 0.8 (0.33–2.33) |
|                   |              |              | No         | 25/22/4             |        |             |                 | 13/12/3  |                    |        |             |                 |
|                   |              | SDAI_remission | Yes       | 15/11/3             | 0.63   | 0.81 (0.34–1.93) | 0.7 (0.34–2.06) | 8/14/9   | 0.25               | 1.62 (0.65–5.12) | 0.2 (0.66–6.34) |
|                   |              |              | No         | 33/34/4             |        |             |                 | 25/17/7  |                    |        |             |                 |
|                   |              | EULAR        | Good/moderate | 34/31/5             | 0.75   | 0.87 (0.37–2.04) | 0.78 (0.36–2.17) | 31/22/5  | 0.013              | 0.16 (0.03–0.78) | 0.02 (0.03–0.73) |
|                   |              |              | No         | 14/15/2             |        |             |                 | 2/9/2     |                    |        |             |                 |
| rs2233945 C>A     | PSORS1C1     | SDAI_LDA     | Yes        | 36/12/1             | 0.012  | 0.35 (0.15–0.80) | 0.023 (0.16–0.87) | 24/19/1  | 0.94               | 0.96 (0.37–2.49) | 0.9 (0.40–2.83) |
|                   |              |              | No         | 25/24/2             |        |             |                 | 15/11/2  |                    |        |             |                 |
|                   |              | SDAI_remission | Yes       | 20/8/1             | 0.3    | 0.62 (0.25–1.54) | 0.38 (0.26–1.67) | 13/8/1   | 0.64               | 0.78 (0.28–2.17) | 0.64 (0.26–2.29) |
|                   |              |              | No         | 41/28/2             |        |             |                 | 26/21/2  |                    |        |             |                 |
|                   |              | EULAR        | Good/moderate | 47/22/1             | 0.074  | 0.46 (0.19–1.09) | 0.11 (0.2–1.18) | 30/26/2  | 0.25               | 2.1 (0.58–7.59) | 0.21 (0.63–8.84) |
|                   |              |              | No         | 15/14/2             |        |             |                 | 9/3/1     |                    |        |             |                 |
| rs734029 A>G      | PTPN2        | SDAI_LDA     | Yes        | 34/14/1             | 0.39   | 0.7 (0.30–1.61) | 0.33 (0.26–1.56) | 32/12/0  | 0.83               | 1.13 (0.38–3.32) | 0.77 (0.39–3.65) |
|                   |              |              | No         | 30/13/0             |        |             |                 | 21/7/0    |                    |        |             |                 |
|                   |              | SDAI_remission | Yes       | 18/10/1             | 0.66   | 1.22 (0.5–3.01) | 0.74 (0.46–3.01) | 15/7/0   | 0.52               | 1.44 (0.48–4.36) | 0.52 (0.44–5.03) |
|                   |              |              | No         | 46/22/0             |        |             |                 | 37/12/0  |                    |        |             |                 |
|                   |              | EULAR        | Good/moderate | 46/22/1             | 0.66   | 0.82 (0.33–2.02) | 0.77 (0.33–2.89) | 43/15/0  | 0.72               | 0.79 (0.21–2.93) | 0.86 (0.22–3.5)  |
|                   |              |              | No         | 18/11/0             |        |             |                 | 9/4/0     |                    |        |             |                 |

"wt" indicates the homozygous genotype for the wild-type allele; "hz" indicates the heterozygous genotype; "var" indicates the homozygous genotype for the variant allele. *P adjusted for sex, DMARDS and ACPA/RF positivity. Significant P values are reported in bold.

doi:10.1371/journal.pone.0169956.t003
The association of PSORS1C1 with a good-moderate EULAR response, detected in the preliminary analysis in the whole cohort, was not confirmed considering each drug separately. Nonetheless, it is worth to highlight that genotypes carrying the variant allele presented a higher frequency in patients with a good/moderate response at 2 years with both drugs (ORadj = 2.35 in the case of ETN; ORadj = 4.24 in the case of ADA), even if this difference did not reach the statistical significance (Padj = 0.21 and Padj = 0.23 respectively).

Fig 1 summarizes the odds ratio of the relevant associations observed between genetic variants and treatment outcome both in the whole RA population and in the two subgroups stratified by the drug (Fig 1).

### Table 4. Association between analysed polymorphisms and response to Adalimumab treatment in RA patients.

| SNP and gene | Target | ADA response | Six months | Two years |
|--------------|--------|--------------|------------|-----------|
|              |        |              | Genotypes w/hz/variant | P (1df) | OR (95% CI) | P adj* | OR adj (95% CI) | Genotypes w/hz/variant | P (1df) | OR (95% CI) | P adj* | OR adj (95% CI) |
| rs33980500 C>T | TRAF3IP2 | SDAI_LDA | Yes | 36/3/0 | 0.11 | 0.3 (0.06–1.4) | 0.11 | 0.25 (0.05–1.37) | 20/3/0 | 0.31 | 0.4 (0.07–2.42) | 0.37 | 0.41 (0.06–2.87) |
|              |        |              | No | 18/5/0 | ND | ND | ND | 10/0/0 | 0.08 | ND | ND |
|              |        | SDAI_remission | Yes | 15/0/0 | 0.09 | ND | 1 | ND | 18/6/0 | 0.08 | ND | ND |
|              |        | EULAR | Good/ moderate | 43/6/0 | 0.76 | 0.77 (0.14–4.34) | 0.73 | 0.71 (0.10–4.86) | 22/2/0 | 0.027 | 0.14 (0.02–0.93) | 0.16 | 0.16 (0.02–1.57) |
|              |        |              | No | 11/2/0 | ND | ND | ND | 6/4/0 | 0.08 | ND | ND |
| rs7574865 G>T | STAT4 | SDAI_LDA | Yes | 26/11/2 | 0.42 | 0.65 (0.23–1.88) | 0.46 | 0.66 (0.22–1.98) | 13/8/2 | 0.55 | 0.64 (0.15–2.72) | 0.48 | 0.58 (0.13–2.61) |
|              |        |              | No | 13/10/0 | ND | ND | ND | 5/6/0 | 0.08 | ND | ND |
|              |        | SDAI_remission | Yes | 10/4/1 | 0.73 | 0.81 (0.24–2.74) | 0.58 | 0.7 (0.2–2.46) | 4/4/2 | 0.33 | 2.1 (0.47–9.44) | 0.37 | 2.12 (0.42–10.81) |
|              |        |              | No | 29/17/1 | ND | ND | ND | 14/10/0 | 0.08 | ND | ND |
|              |        | EULAR | Good/ moderate | 33/14/2 | 0.16 | 0.42 (0.12–1.44) | 0.16 | 0.39 (0.11–1.45) | 13/9/2 | 0.82 | 0.85 (0.19–3.71) | 0.53 | 0.58 (0.11–3.16) |
|              |        |              | No | 6/7/0 | ND | ND | ND | 8/2/1 | 0.09 | ND | ND |
| rs2233945 C>A | PSORS1C1 | SDAI_LDA | Yes | 29/9/1 | 0.075 | 0.38 (0.13–1.12) | 0.073 | 0.35 (0.11–1.10) | 17/6/0 | 0.94 | 0.94 (0.19–4.76) | 0.88 | 0.88 (0.16–4.8) |
|              |        |              | No | 12/9/2 | ND | ND | ND | 8/2/1 | 0.08 | ND | ND |
|              |        | SDAI_remission | Yes | 11/3/1 | 0.5 | 0.64 (0.18–2.33) | 0.43 | 0.58 (0.15–2.2) | 10/0/0 | 0.024 | ND | 1 | ND |
|              |        |              | No | 30/15/2 | ND | ND | ND | 15/8/1 | 0.16 | ND | ND |
|              |        | EULAR | Good/ moderate | 32/15/2 | 0.79 | 1.20 (0.32–4.46) | 0.75 | 1.25 (0.32–4.85) | 16/8/0 | 0.16 | 4.5 (0.48–42) | 0.23 | 4.24 (0.40–44.55) |
|              |        |              | No | 9/3/1 | ND | ND | ND | 9/0/1 | 0.09 | ND | ND |
| rs7234029 A>G | PTPN2 | SDAI_LDA | Yes | 30/8/1 | 0.79 | 0.85 (0.26–2.8) | 0.87 | 0.91 (0.27–3.04) | 14/8/1 | 0.072 | 6.43 (0.7–59.17) | 0.09 | 6.94 (0.73–65.68) |
|              |        |              | No | 17/4/2 | ND | ND | ND | 10/0/1 | 0.09 | ND | ND |
|              |        | SDAI_remission | Yes | 14/0/1 | 0.069 | 0.17 (0.02–1.41) | 0.09 | 0.15 (0.02–1.32) | 8/1/1 | 0.44 | 0.5 (0.09–2.93) | 0.4 | 0.43 (0.06–2.99) |
|              |        |              | No | 33/12/2 | ND | ND | ND | 16/7/1 | 0.09 | ND | ND |
|              |        | EULAR | Good/ moderate | 40/7/2 | 0.038 | 0.26 (0.07–0.97) | 0.06 | 0.27 (0.07–1.03) | 16/7/1 | 0.44 | 2 (0.34–11.70) | 0.37 | 2.43 (0.35–17.08) |
|              |        |              | No | 7/5/1 | ND | ND | ND | 8/1/1 | 0.16 | ND | ND |

*hz* indicates the heterozygous genotype; "var" indicates the homozygous genotype for the variant allele.

* P adjusted for sex, DMARDS, ACPA/RF positivity. Significant P values are reported in bold. Between analysed polymorphisms and response to Adalimumab treatment in RA patients.

doi:10.1371/journal.pone.0169956.t004
STAT4, PTPN2, PSORS1C1 and TRAF3IP2 SNPs in Response to TNF-Inhibitors
Discussion

TNF-i have shown a good efficacy in the treatment of chronic inflammatory arthropathies, including RA [27]. However, a consistent part of patients does not reach the therapeutic targets of remission and LDA during TNF-i treatment. Evidence suggested the presence of a confined period of time, defined “window of opportunity”, in which RA patients are more susceptible to treatment [28, 29]. Moreover, a prolonged disease activity and a long disease duration at treatment initiation have been associated with unfavorable outcomes in RA [29, 30]. Furthermore, RA can cause progressive disability that leads to high direct and indirect costs for the health system [31]. Therefore, the identification of specific predicting factors of response to a specific treatment would be enormously useful in the clinical practice to select the patient that would benefit or not from the treatment [27, 32]. Candidate genes encoding proteins involved in the immune response have been fairly investigated to search for a possible association with TNF-i response in several autoimmune diseases, including RA [33–36]. However, validated genomic biomarkers currently do not significantly allow the identification of non-responders before treatment in RA [15].

In this study, we evaluated the potential role of SNPs in STAT4, PTPN2, PSORS1C1, and TRAF3IP2 genes on the response to ETN and ADA treatment in RA patients. We selected these genes on the base of our previous studies that aimed to verify the association of common variants with different autoimmune diseases susceptibility [21, 37–39]. In our previous study, STAT4, one of the most associated gene with RA susceptibility, related with a higher susceptibility to develop RA and with ACPA positivity, while SNPs in PSORS1C1 and PTPN2 genes were differently associated with joint damage in RA, even if we did not observe an association with RA susceptibility [21]. We considered as a candidate gene also TRAF3IP2 that encodes for Act1, an IL-17R adaptor protein sharing intracellular signal transduction molecules with the TNF-α signaling pathway, serving both as negative regulator of adaptive immunity and as a positive signaling adaptor in IL17-mediated immune responses [40, 41].

The results of the present study showed the presence of some associations of the investigated SNPs with remission, LDA, and EULAR response. Several lines of evidence in the literature demonstrated that ADA and ETN exert a different effect on innate and adaptive immune cell population in RA treated patients despite their similar effectiveness [42–44]. Our preliminary data seems to suggest that the associations may be drug specific. However, given the small number of analyzed subjects, these results could be attributable to a low power of the study and need to be further investigated in larger samples. Regarding the response to ETN treatment, we observed a worse EULAR response in patients carrying the variant allele of STAT4 rs7574865 after 2 years of treatment and a lack of LDA achievement at 6 months of treatment in patients carrying the variant allele of PSORS1C1 rs2233945 SNP. These two associations were not present in the group of patients treated with ADA in which, on the contrary, we observed a worse EULAR response in patients carrying the variant allele of TRAF3IP2 after 2 years of treatment and the variant allele of PTPN2 after 6 months of treatment.

A recent study reported that the T allele of rs7574865 is significantly associated with higher levels of STAT4 mRNA and protein expression in a population of patients with early arthritis.
Since STAT4 is involved in the signaling of IL-12, IL-23, and IFN-γ, it has been suggested that patients carrying the rs7574865 minor allele might show stronger T helper (Th1) and Th17 cytokine responses that are represented in RA [46–48]. ETN seems able to downregulate both the Th1 and Th17 [49], therefore we could hypothesize that patients carrying the variant allele are less sensitive to the ETN effect. On the contrary, we could not demonstrate an association with ADA treatment that might be explained by previous findings suggesting that ADA seems to increase STAT4 activation in CD4+ T cells from RA patients [50].

We found that the variant allele of PTPN2 (rs7234029) was associated with a worse EULAR response at 6 months of ADA treatment. The same polymorphism, located in an intron region, was associated with a poor prognosis in a Portuguese population of RA patients treated with DMARDs and biologics [51]. PTPN2 was significantly overexpressed in synovial tissue samples from RA patients [52]. Interestingly, we observed a high frequency of bone erosions in patients carrying the variant allele [21]; this could be congruent with the worse response to treatment in patients carrying such variant. Although there are no functional studies on rs7234029 SNP, an in silico analysis revealed that it modulates potentially the binding sites of several transcription factors involved in inflammation [53]. Therefore, further analysis should firstly replicate our preliminary data on large cohort of patients and then define the potential effect of this SNP on different drug’s mechanism of action.

PSORS1C1 can affect IL-17 secretion that plays important roles in synovial inflammation and bone destruction in RA [54]. A significant increase in expression of PSORS1C1 in RA synovial tissues has been also described [55]. The functional role of rs2233945 is not known; the SNP is located in an intronic region and therefore we can speculate that it could be involved in expression regulation. Patients carrying the variant allele of this SNP treated with ETN are less likely to achieve LDA at 6 months suggesting that this genetic variation may interfere with the drug mechanism of action possibly increasing the IL-17 response. However, an opposite effect was suggested at 2 years of treatment in the whole RA population and in particular in the ADA group of patients. This contradictory result may be attributed to either a different mechanism of action of ADA in those patients carrying the variant allele, or to a bias related to the small number of analyzed patients and the dropouts at 2 years. Functional studies on this SNP will give important information on its putative role in TNF-i treated patients.

Regarding TRAF3IP2, we observed that remission and LDA at 6 months of treatment were not achieved in patients carrying the variant genotype, considering patients treated with ETN and ADA together, but this result was not replicated in the two subgroups stratified by the drug. TRAF3IP2 product interacts with TRAF proteins; in the TRAF gene family, TRAF1 is a negative regulator of TNF receptor that was identified as a risk locus for RA in a GWAS [56]. The rs33980500 SNP decreases the binding with TRAF6 and this could also alter TRAF2 and TRAF5 protein interactions within the IL-17R signaling pathway, leading to increased neutrophil chemotaxis and an enhanced immune response [57]. Recently, TRAF1 has been investigated in relation to TNF-i response by Canhao et al., who reported in Portuguese RA patients an association of the minor (G) allele of rs3761847 in the TRAF1/C5 with a poor response to TNF-i treatment at 6 months [58]. However, another study in a Greek population did not confirm the association of TRAF1 with TNF-i treatment [59].

This study presents some limitations. First, we have analyzed only one SNP for each selected gene. Indeed, it is possible that other SNPs (or a combination of SNPs) in these genes (and in other genes) could play a role in response to TNF-i treatment. Moreover, the small number of investigated patients may represent a bias that can confound the interpretation of the results, especially in the analysis concerning the two subgroups stratified by the drug. Given the limited number of patients, we have not performed the multiple comparisons correction, and therefore our results should be considered as preliminary data. Further studies are necessary to replicate
our findings in a larger cohort of RA patients together with functional studies in order to confirm and better explore the contribution of these SNPs in the treatment response.

**Author Contributions**

**Conceptualization:** RP PC CC. C. Perricone.

**Data curation:** PC BK CC.

**Formal analysis:** CC SR C. Perricone.

**Investigation:** PC PT CC C. Perricone.

**Methodology:** PC PT CC SR AL C. Politi.

**Project administration:** RP PB.

**Resources:** PC PT BK RP GN PB.

**Software:** CC C. Perricone.

**Supervision:** RP PB.

**Validation:** PC CC.

**Visualization:** PC PT CC.

**Writing – original draft:** PC PT CC C. Politi.

**Writing – review & editing:** PC PT RP CC PB GN.

**References**

1. Combe B. (2009) Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 23: 59–69. doi: 10.1016/j.berh.2008.11.006 PMID: 19233046

2. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al. (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75: 3–15. doi: 10.1136/annrheumdis-2015-207524 PMID: 25969430

3. Smolen JS, Aletaha D, McInnes IB. (2016) Rheumatoid arthritis. Lancet. 388(10055):2023–2038. doi: 10.1016/S0140-6736(16)30173-8 PMID: 27156434

4. Coniglio P, Chimienti MS, Triggianese P, Ballanti E, Sunzini F, Duca I, Perricone R. (2016) Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line anti-tumour necrosis factor. J Int Med Res 44(1 suppl): 90–94. doi: 10.1177/0300060515593262 PMID: 27683148

5. Daen CI, Morel J. (2014) Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm 2014:386148. doi: 10.1155/2014/386148 PMID: 24523570

6. Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C. (2016) The Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken)

7. Quintana-Duque MA, Rondon-Herrera F, Mantilla RD, Calvo-Paramo E, Yunis JJ, Varela-Nariño A, et al. (2016) Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study. Clin Rheumatol 35: 1463–1473. doi: 10.1007/s10067-016-3246-5 PMID: 27041382

8. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeeke T et al. (2012) Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis 71: 1815–1819. doi: 10.1136/annrheumdis-2011-201109 PMID: 22615458

9. Scrivo R, Coniglio P, Ricciere V, Di Franco M, Alessandri C, Spadaro A, et al. (2015) Distribution of IL-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different
10. Katchamart W, Johnson S, Lin HJ, Phumethum V, Sailiot C, Bombardier C. (2010) Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken) 62: 1128–1143.

11. Alessandri C, Conti F, Conigliaro P, Mancini R, Massaro L, Valesini G. (2009) Seronegative Autoimmune Diseases. Ann N Y Acad Sci 1173: 52–59. doi: 10.1111/j.1749-6632.2009.04806.x PMID: 19758132

12. Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, et al. (2012) Replication of association of the PTGER3 gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64: 665–670. doi: 10.1002/art.33381 PMID: 21952740

13. Acosta-Colman I, Palau NF, Tornero JF, Fernandez-Nebro AF, Blanco FF, Gonzalez-Alvaro IF, et al. (2013)GWAS replication study confirms the association of PDE3A-SLC01C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 14: 727–734. doi: 10.2217/pgs.13.60 PMID: 23651021

14. Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Locht H, et al. (2015) Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis. PLoS One 10: e0139781. doi: 10.1371/journal.pone.0139781 PMID: 26440629

15. Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, et al. (2016) Crowdsourced assessment of common genetic contribution to predicting anti-TNF response in rheumatoid arthritis. Nat Commun 7: 12460. doi: 10.1038/ncomms12460 PMID: 27549343

16. Nabi G, Akhter N, Wahid M, Bhatia K, Mandal RK, Dar SA, et al. (2016) Meta-analysis reveals PTPN22 1858C/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian populations. Autoimmunity 49: 197–210. doi: 10.3109/08916934.2015.1134514 PMID: 26763276

17. Scott IC, Rijsdijk F, Walker J, Quist J, Spain SL, Tan R, et al. (2015) Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis? Rheumatology 42: 1131–1140. doi: 10.1093/rheumatology/kev421 PMID: 25979711

18. Elshazli R, Settin A. (2015) Association of PTPN22 rs2476601 and STAT4 rs7574865 polymorphisms with rheumatoid arthritis: A meta-analysis update. Immunobiology 220: 1012–1024. doi: 10.1016/j.imbi.2015.04.003 PMID: 25963842

19. Aradi B, Kato M, Filkova M, Karouzakis E, Klein K, Scharl M, et al. (2015) Protein tyrosine phosphatase nonreceptor type 2: an important regulator of interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Arthritis Rheumatol 67: 2624–2633. doi: 10.1002/art.39256 PMID: 26139109

20. Solus JF, Chung CP, Oeser A, Li C, Rho YH, Bradley KM, et al. (2015) Genetics of serum concentration of IL-6 and TNFα in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis. Clin Rheumatol 34: 1375–1382. doi: 10.1007/s10067-015-2881-6 PMID: 25652333

21. Ciccacci C, Conigliaro P, Perricone C, Rufini S, Triggianese P, Politi C, et al. (2016) Polymorphisms in STAT4, IL10, PSORS1C1, PTPN2 and MIR146A genes are differently associated with prognostic factors in Italian patients affected by Rheumatoid Arthritis. Clin Exp Immunol 186: 157–163. doi: 10.1111/cei.12831 PMID: 27342690

22. Sun H, Xia Y, Wang L, Wang Y, Chang X. (2013) PSORS1C1 may be involved in rheumatoid arthritis. Immunol Lett 153: 9–14. doi: 10.1016/j.imlet.2013.06.001 PMID: 23769905

23. Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, et al. (2015) Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet 97: 816–836. doi: 10.1016/j.ajhg.2015.10.019 PMID: 26626624

24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 62: 2569–2581. doi: 10.1002/art.27584 PMID: 20672595

25. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42: 244–257. PMID: 12595618

26. van Gestel AM, Prevoo ML, van ’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39: 34–40. PMID: 8546736

27. Cuppen BV, Welsing PM, Sprengers JJ, Bijlswma JW, Marijnissen AC, van Laar JM, et al. (2016) Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology 55: 826–839. doi: 10.1093/rheumatology/kev421 PMID: 26715775
28. Cush JJ. (2007) Early rheumatoid arthritis—is there a window of opportunity? J Rheumatol Suppl. 80:1–7. PMID: 17985417

29. van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 74: 806–812. doi: 10.1136/annrheumdis-2014-206047 PMID: 25561360

30. Chimenti MS, Triggianese P, Coniglio P, Candi E, Melino G, Perricone R. (2015) The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis 6:e1887. doi: 10.1038/cddis.2015.246 PMID: 26379192

31. Wallman JK, Eriksson J, Nilsson JÅ, Olofsson T, Kristensen LE, Neovius M, et al. (2016) Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden. J Rheumatol 43: 1292–1299. doi: 10.3899/jrheum.150617 PMID: 27252420

32. Coniglio P, Chimenti MS, Triggianese P, Sunzini F, Novelli L, Perricone C, et al. (2016) Autoantibodies in inflammatory arthritis. Autoimmun Rev 15: 673–683. doi: 10.1016/j.autrev.2016.03.003 PMID: 26970491

33. Tong Q, Zhao L, Qian XD, Zhang LL, Xu X, Dai SM, et al. (2013) Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics 14: 1691–700. doi: 10.2217/pgs.13.146 PMID: 24192118

34. Prieto-Pérez R, Almoquera B, Cabaleiro T, Hakonarson H, Abad-Santos F. (2016) Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease. Int J Mol Sci 17: 225. doi: 10.3390/ijms17020225 PMID: 26861312

35. Oliver J, Plant D, Webster AP, Barton A. (2015) Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomark Med 9: 499–512. doi: 10.2217/bmm.15.18 PMID: 26079957

36. Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrozo F, Celis R, et al. (2012) Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 79: 591–596. doi: 10.1016/j.jbspin.2012.02.003 PMID: 22480748

37. Ciccacci C, Biancone L, Di Fusco D, Ranieri M, Condino G, Giardina E, et al. (2013) TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis 7: 44–52. doi: 10.1016/j.crohns.2012.02.020 PMID: 22445837

38. Perricone C, Ciccacci C, Ceccarelli F, Di Fusco D, Spinelli FR, Cipriano E, et al. (2013) TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics 65: 703–709. doi: 10.1007/s00251-013-0717-6 PMID: 23836313

39. Ciccacci C, Perricone C, Ceccarelli F, Rufini S, Di Fusco D, Alessandri C, et al. (2014) A multicentric genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene. PLoS One 9:e111991. doi: 10.1371/journal.pone.0111991 PMID: 25369137

40. Iwakura Y, Ishigame H, Saijo S, Nakae S. (2011) Functional specialization of interleukin-17 family members. Immunity 34: 149–162. doi: 10.1016/j.immuni.2011.02.012 PMID: 21349428

41. Urabe S, Isomoto H, Ishida T, Maeda K, Inamine T, Kondo S, et al. (2015) Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease. Biomed Res Int 2015: 416838. doi: 10.1155/2015/416838 PMID: 26558270

42. Coniglio P, Triggianese P, Perricone C, Chimenti MS, Di Muzio G, Ballanti E, et al. (2014) Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clin Exp Immunol 177: 234–243. doi: 10.1111/cei.12335 PMID: 24664041

43. Furst DE, Wallis R, Broder M, Beenhouwer DO. (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36: 159–167. doi: 10.1016/j.semarthr it.2006.02.001 PMID: 16884970

44. Prajapati R, Plant D, Barton A. (2011) Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 12: 1571–1585. doi: 10.2217/pgs.11.114 PMID: 22044414

45. Lamana A, López-Santalla M, Castillo-González R, Ortiz AM, Martín JC, García-Vicuña R, González-Álvaro I. (2015) The Minor Allele of rs7574865 in the STAT4 Gene Is Associated with Increased mRNA and Protein Expression. PLoS One 10:e0142683. doi: 10.1371/journal.pone.0142683 PMID: 26569699

46. Korman BD, Kastner DL, Gregersen PK, Remmers EF. (2008) STAT4: genetics, mechanisms, and implications for autoimmunity. Curr allergy asthma rep 8: 398–403. PMID: 18682104
47. Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S, et al. (2000) STAT4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol 164: 4659–4664. PMID: 10779770
48. Patakas A, Benson RA, Withers DR, Conigliaro P, McInnes IB, Brewer JM, Garside P. (2012) Th17 effector cells support B cell responses outside of germinal centres. PLoS One. 7: e49715. doi: 10.1371/journal.pone.0049715 PMID: 23166752
49. Antiga E, Volpi W, Cardilichchia E, Maggi L, Fili L, Manueli C, et al. (2012) Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. J Clin Immunol 32: 1221–1232. doi: 10.1002/jcim.20139 PMID: 22699761
50. Aerts NE, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS. (2010) T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis. Clin Exp Rheumatol 28: 208–214. PMID: 20483042
51. Mourão AF, Santos MJ, Mendonça S, Oliveira-Ramos F, Salgado M, Estanqueiro P, et al. (2015) Genetic Predictors of Poor Prognosis in Portuguese Patients with Juvenile Idiopathic Arthritis: Data from Reuma.pt. J Immunol Res 2015: 706515. doi: 10.1155/2015/706515 PMID: 26504852
52. Aradi B, Kato M, Filkova M, Karouzas E, Klein K, Scharl M, et al. (2015) Protein tyrosine phosphatase nonreceptor type 2: an important regulator of interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Arthritis Rheumatol 67: 2624–2633. doi: 10.1002/art.39256 PMID: 26139109
53. Glas J, Wagner J, Seiderer J, Olszak T, Wetze M, Beigel F, et al. (2012) PTPN2 gene variants are associated with susceptibility to both Crohn’s disease and ulcerative colitis supporting a common genetic disease background. PLoS One 7: e33682. doi: 10.1371/journal.pone.0033682 PMID: 22457781
54. Moon YM, Yoon BY, Her YM, Oh HJ, Lee JS, Kim KW, et al. (2012) IL-32 and IL-17 interactand have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther 14: R246. doi: 10.1186/ar4089 PMID: 23148861
55. Sun H, Xia Y, Wang L, Wang Y, Chang X. (2013) PSORS1C1 may be involved in rheumatoid arthritis. Immunol Lett 153: 9–14. doi: 10.1016/j.imlet.2013.06.001 PMID: 23769905
56. Plenge RM, Jedelstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. (2007) TRAF1-C5 as a risk locus for rheumatoid arthritis—a genomewide study. N Engl J Med 357: 1199–1209. doi: 10.1056/NEJMoa073491 PMID: 17904836
57. Doyle MS, Collins ES, FitzGerald OM, Pennington SR. (2012) New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis. Arthritis Res Ther 14: 226. doi: 10.1186/ar4071 PMID: 23116200
58. Canhão H, Rodrigues AM, Santos MJ, Carmona-Fernandes D, Bettencourt BF, Cui J, et al. (2015) TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. Biomed Res Int 2015: 490295. doi: 10.1155/2015/490295 PMID: 25834819
59. Zervou M, Myrihanou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F, et al. (2013) Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS One 8: e74375. doi: 10.1371/journal.pone.0074375 PMID: 24040234